Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 289-550-2 | CAS number: 89923-62-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1980-1981
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Sodium 1-amino-9,10-dihydro-9,10-dioxo-4-[[3-[(1-oxopropyl)amino]phenyl]amino]anthracene-2-sulphonate
- EC Number:
- 289-550-2
- EC Name:
- Sodium 1-amino-9,10-dihydro-9,10-dioxo-4-[[3-[(1-oxopropyl)amino]phenyl]amino]anthracene-2-sulphonate
- Cas Number:
- 89923-62-6
- Molecular formula:
- C23H19N3O6S.Na
- IUPAC Name:
- sodium 1-amino-9,10-dioxo-4-[(3-propanamidophenyl)amino]-9,10-dihydroanthracene-2-sulfonate
- Test material form:
- other: solid
- Details on test material:
- None
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: RAIf (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation:7 to 8 weeks old
- Housing: During the treatment and observation period the animals were housed in groups of 5 in Macrolon cages (type 3), individually marked with picric acid.
- Diet: ad libitum (rat food - NAFAG, Gossau SG)
- Water: ad libitum
- Acclimation period: Prior to treatment the animals were adapted to our laboratories for a minimum of 4 days.
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 2 °C
- Humidity: 55 ± 10 %
- Photoperiod:10 hours light cycle day.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on oral exposure:
- VEHICLE
Polyethylene glycol, Fluka AG Buchs SG, Art. 81170.
MAXIMUM DOSE VOLUME APPLIED: 10, 20 ml/kg body-weight
DOSAGE PREPARATION:
FAT 20242/A was diluted to achieve the corresponding dosage level. Before treatment the suspension was homogeneously dispersed with an Ultra-Turrax and during treatment it was kept stable with a magnetic stirrer.
Animals fasted overnight were treated by single oral intubation. - Doses:
- 1000, 2500, 5000 and 7000 mg/kg bw
- No. of animals per sex per dose:
- 1000 mg/kg: 5 males and 5 females
2500 mg/kg: 10 males and 10 females
5000 mg/kg: 10 males and 10 females
7000 mg/kg: 10 males and 10 females - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days.
- Frequency of observations: daily for mortality and clinical signs.
- Weighing: day 1, day 7 and day 14.
- Necropsy of survivors performed: yes. - Statistics:
- None
Results and discussion
- Preliminary study:
- None
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 500 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Males (rate of deaths):
1000 mg/kg: 0 %
2500 mg/kg: 10%
5000 mg/kg: 30%
7000 mg/kg: 0%
Females (rate of deaths)
1000 mg/kg: 0 %
2500 mg/kg: 20%
5000 mg/kg: 80%
7000 mg/kg: 10% - Clinical signs:
- other: Sedation, dyspnoea, exophthalmos, ruffled fur, diarrhoea, body position (ventral, lateral and curved) and convulsions were the clinical signs observed. The clinical signs reversed by day 8.
- Gross pathology:
- No compound related gross organ changes were observed.
- Other findings:
- None
Any other information on results incl. tables
Signs and symptoms at 1000 mg/kg bw:
Hours | Days | |||||||||||||||||
Signs and symptoms |
1 | 2 | 3 | 5 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
Sedation | + | + | + | + | + | + | ||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | + | + | |||||||
Exophthalmos | + | + | + | + | + | + | + | |||||||||||
Ruffled fur | ++ | ++ | ++ | ++ | ++ | + | + | + | + | + | + | |||||||
Diarrhoea | + | + | ||||||||||||||||
Body position curved | + | + | + | + | + | + | + | + | + |
Signs and symptoms at 2500 mg/kg:
Hours | Days | |||||||||||||||||
Signs and symptoms | 1 | 2 | 3 | 5 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
Sedation | + | + | + | + | + | + | ||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | + | + | |||||||
Exophthalmos | + | + | + | + | + | + | ||||||||||||
Ruffled fur | ++ | ++ | ++ | ++ | ++ | + | + | + | + | + | + | |||||||
Diarrhoea | + | + | + | + | + | |||||||||||||
Body position curved | + | + | + | + | + | + | + | + | + | + | + |
Signs and symptoms at 5000 mg/kg bw:
Signs and symptoms | Hours | Days | ||||||||||||||||
1 | 2 | 3 | 5 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | + | + | + | + | + | |||||||||||||
Dyspnoea | + | + | + | + | + | + | + | + | + | + | + | |||||||
Exophthalmos | + | + | + | + | + | |||||||||||||
Ruffled fur | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | + | + | |||||||
Diarrhoea | ++ | ++ | ++ | + | + | + | + | |||||||||||
Body position ventral | + | + | + | + | ||||||||||||||
Body position lateral | + | + | + | + | ||||||||||||||
Body position curved | + | + | + | + | + | + | + | + | + | + | + | |||||||
Convulsions | ++ | + | + |
Signs and symptoms at 7000 mg/kg bw:
Signs and symptoms | hours | Days | ||||||||||||||||
1 | 2 | 3 | 5 | 24 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
Sedation | ++ | ++ | ++ | ++ | + | + | ||||||||||||
Dyspnoea | + | + | ++ | ++ | + | + | + | + | + | + | + | |||||||
Exophthalmos | + | + | + | + | + | + | ||||||||||||
Ruffled fur | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | + | + | + | |||||||
Diarrhoea | + | ++ | ++ | ++ | + | |||||||||||||
Body position ventral | + | + | + | + | ||||||||||||||
Body position lateral | + | + | + | + | ||||||||||||||
Body position curved | + | + | + | + | + | + | + | + | + | + | + | |||||||
Convulsions | + | + | + | + |
BODY WEIGHT CHANGE:
Dose (mg/kg bw) | |||||
1000 | 2500 | 5000 | 7000 | ||
Day 1 (males) | Mean bodyweight/SD (g) | 184 /2.8 | 176 /2.3 | 184 /1.5 | 210 /10.1 |
Day 1 (females) | Mean bodyweight/SD (g) | 170 /2.5 | 167 /6.9 | 171 /1.4 | 182 /5.6 |
Day 7 (males) | Mean bodyweight/SD (g) | 243 /6.3 | 237 /2.7 | 228 /4.0 | 258 /8.2 |
Day 7 (females) | Mean bodyweight/SD (g) | 204 /4.1 | 205 /5.0 | - | 207 /3.5 |
Day 14 (males) | Mean bodyweight/SD (g) | 275 /5.1 | 292 /2.6 | 276 /3.5 | 298 /9.8 |
Day 14 (females) | Mean bodyweight/SD (g) | 227 /9.3 | 192 /25.9 | - | 232 /5.1 |
The surviving animals recovered within 7 days. All rats were submitted to a necropsy whenever they died, survivors at the end of the observation period.
Applicant's summary and conclusion
- Interpretation of results:
- study cannot be used for classification
- Conclusions:
- The acute oral LD50 of FAT 20242/A in rats of both sexes observed over a period of 14 days is >2500 mg/kg bw.
- Executive summary:
A study was carried out for the determination of the acute oral LD50 of FAT 20242/A using 80 Tif. RAI rats by following the methodology similar to OECD TG 401. Before administration by oral intubation, FAT 20242/A was suspended in polyethylene glycol (PEG 400). The test material was administered at 1000, 2500, 5000 and 7000 mg/kg bw respectively.
At 1000 mg/kg bw, no mortality was seen. However, 15, 55 and 50 % mortality was seen at 2500, 5000 and 7000 mg/kg bw, respectively. Sedation, dyspnoea, exophthalmos, ruffled fur, diarrhoea, body position (ventral, lateral and curved) and convulsions were the clinical signs observed. The clinical signs reversed by day 8. At necropsy, no substance related gross organ changes were seen. In conclusion, the acute oral LD50 of FAT 20242/A in rats of both sexes observed over a period of 14 days is greater than 2500 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.